PET vs. MRI in re-irradiation for recurrent glioblastoma: insights from a Phase II trial

Ilinca Popp, MD, from University Medical Center Freiburg, Freiburg, Germany, discusses a prospective, multicenter Phase II trial (NCT01252459) comparing FET-PET and T1Gd-MRI-based target volume delineation in re-irradiation for recurrent glioblastoma (rGBM). Despite expectations, FET-PET-based treatment did not improve progression-free survival (PFS) or overall survival (OS) compared to T1Gd-MRI-based treatment. Both options were deemed valid, with stereotactic re-irradiation being safe. FET-PET investigation was well tolerated, maintaining its diagnostic role in differentiating rGBM progression from post-therapeutic changes. Dr Popp emphasizes the importance of identifying the specific patient subgroups for whom these investigations are most beneficial, noting that while PET imaging did not alter diagnostic sensitivity or specificity, it did result in differences in target volumes compared to MRI. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Видео PET vs. MRI in re-irradiation for recurrent glioblastoma: insights from a Phase II trial канала VJOncology